Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers

肿瘤浸润淋巴细胞治疗人乳头瘤病毒阳性癌症

• 批准号: 8763553
• 负责人: Christian Hinrichs
• 金额: $ 22.71万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8763553
• 关键词: Adoptive Transfer; Anus; Clinical; Clinical Trials; Disease; Family psychotherapy; Human Papillomavirus; In Vitro; Laboratories; Laboratory Study; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Mediating; Metastatic Melanoma; Mutate; Oncogene Proteins; Oropharyngeal; Phenotype; Proteins; Specificity; T cell therapy; T-Lymphocyte; Testing; Time; Tumor-Infiltrating Lymphocytes; Vagina; Viral; Vulva; Work; base; in vivo; innovation; melanoma; response; tumor infiltrating lymphocyte therapy

The purpose of this project is to determine the objective clinical response rate of TIL therapy in HPV-positive cancers and to investigate the specificity, phenotype, and function of TIL from HPV-positive cancers in vitro and in vivo. Our laboratory has established the feasibility of generating TIL from HPV-positive cancers at clinical grade and scale. Based on that work we have initiated a clinical trial of TIL from HPV-positive cancers (HPV-TIL) with the primary end point of objective clinical response rate. The trial is open to accrual at this time. Laboratory studies to characterize HPV-TIL and to innovate the next generate of cellular therapies for this family of diseases are ongoing.

本项目旨在确定hpv阳性肿瘤TIL治疗的客观临床有效率，并在体外和体内研究hpv阳性肿瘤TIL的特异性、表型和功能。我们的实验室已经在临床分级和规模上确定了从hpv阳性肿瘤中产生TIL的可行性。在此基础上，我们启动了一项针对hpv阳性癌症（HPV-TIL）的TIL临床试验，主要终点为客观临床反应率。审判目前正在进行中。目前正在进行实验室研究，以确定HPV-TIL的特征，并为这一疾病家族创新下一代细胞疗法。